Takeda Gets Chinese Regulatory Approval for Livtencity
By Ben Glickman
Livtencity, Takeda Pharmaceutical's treatment for cytomegalovirus, has received approval from Chinese regulators in certain cases.
The Japanese pharmaceutical company said Thursday that Livtencity, which goes by generic name maribavir, was approved by the National Medical Products Administration of China for treating adults with post-hematopoietic stem cell transplant or solid organ transplant cytomegalovirus infection or disease.
The approval specifically relates to cases that did not respond to other treatments.
The company secured breakthrough therapy designation by the China Center for Drug Evaluation in 2021.
Livtencity was originally approved in the U.S. for the treatment of cytomegalovirus infection and disease in 2021.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 21, 2023 16:27 ET (21:27 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Occidental Earnings: CrownRock Transaction Should Still Close, but Not Until the Third Quarter
-
After Earnings, Is Apple Stock a Buy, a Sell, or Fairly Valued?
-
Uber Earnings: Network Effect Continues to Drive Profitable Growth for Uber
-
Undervalued by 28%, This Stock Is a Buy for Patient Investors
-
10 Best Growth Stocks to Buy for the Long Term
-
The Best Technology Stocks to Buy
-
After Earnings, Is Coke Stock a Buy, a Sell, or Fairly Valued?
-
Disney Earnings: Improved Streaming Results Come at the Expense of Continued Linear Weakness